Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non–Muscle-Invasive Bladder Cancer

医学 多西紫杉醇 膀胱癌 癌症 内科学 挽救疗法 泌尿科 肿瘤科 化疗
作者
Ian M. McElree,Vignesh T. Packiam,Ryan L. Steinberg,Sarah L. Mott,Paul T. Gellhaus,Kenneth G. Nepple,Michael A. O’Donnell
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:208 (5): 969-977 被引量:12
标识
DOI:10.1097/ju.0000000000002848
摘要

Intravesical gemcitabine-docetaxel has emerged as an efficacious and well-tolerated salvage therapy for non-muscle-invasive bladder cancer. However, further rescue therapies are needed for subsequent recurrences or intolerance, particularly when cystectomy is refused or precluded. Valrubicin is a U.S. Food and Drug Administration-approved agent for bacillus Calmette-Guérin unresponsive disease, yet as monotherapy has demonstrated poor efficacy. We report our experience with sequential intravesical valrubicin and docetaxel as a rescue therapy for non-muscle-invasive bladder cancer.We retrospectively identified all patients with recurrent non-muscle-invasive bladder cancer treated with valrubicin and docetaxel between April 2013 and June 2021. Patients received weekly sequential intravesical instillations of 800 mg valrubicin and 37.5 mg docetaxel for 6 weeks. If disease-free at first follow-up, monthly maintenance of 2 years was initiated. The primary outcome was recurrence-free survival, assessed using the Kaplan-Meier method.The analysis included 75 patients with median follow-up of 21 months (IQR: 13-37). Twelve patients with low-grade disease had a 73% recurrence-free survival at 2 years. Sixty-three patients with recurrent high-grade disease had a 38% 2-year high-grade recurrence-free survival. Forty-two (56%) patients had carcinoma in situ present; recurrence-free survival was similar for those with and without carcinoma in situ (P = .63). Two patients died of metastatic bladder cancer while 10 underwent cystectomy. Among patients with high-grade disease, overall, cancer-specific, and cystectomy-free survivals were 87%, 96%, and 84% at 2 years, respectively. Adverse events included bladder spasms (n = 18), urinary frequency (n = 10), and dysuria (n = 8). Two patients could not tolerate valrubicin and docetaxel induction.In a heavily pretreated population, our results suggest valrubicin and docetaxel is an effective rescue treatment for patients with recurrent non-muscle-invasive bladder cancer. Further prospective evaluation is needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
喻箴发布了新的文献求助10
刚刚
微笑的桐发布了新的文献求助10
刚刚
不良帅完成签到,获得积分10
1秒前
IvanMcRae应助蓝色的云采纳,获得10
2秒前
老朱发布了新的文献求助10
2秒前
2秒前
zxf发布了新的文献求助10
2秒前
迷人问兰完成签到,获得积分10
5秒前
李富贵完成签到,获得积分20
6秒前
哭泣的俊驰完成签到,获得积分20
6秒前
6秒前
7秒前
xyg发布了新的文献求助10
9秒前
量子星尘发布了新的文献求助10
9秒前
10秒前
YouzhiYe关注了科研通微信公众号
11秒前
仁爱的尔蓝完成签到 ,获得积分10
11秒前
zXX发布了新的文献求助10
12秒前
苏苏发布了新的文献求助10
12秒前
13秒前
小木木壮发布了新的文献求助50
14秒前
害怕的友蕊完成签到,获得积分20
14秒前
老迟到的土豆完成签到 ,获得积分10
15秒前
15秒前
ALICE发布了新的文献求助10
16秒前
烟花应助郭志晟采纳,获得10
16秒前
17秒前
Luke完成签到,获得积分10
17秒前
曾经二娘发布了新的文献求助10
17秒前
研友_Z3vN0n发布了新的文献求助10
17秒前
summer完成签到,获得积分10
17秒前
水流众生完成签到 ,获得积分10
17秒前
圣殿幻龙完成签到,获得积分10
18秒前
米粒发布了新的文献求助10
19秒前
Stroeve完成签到,获得积分10
19秒前
调皮德地完成签到,获得积分20
20秒前
水果完成签到,获得积分10
20秒前
庄冬丽发布了新的文献求助10
20秒前
务实的香彤完成签到,获得积分20
21秒前
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970048
求助须知:如何正确求助?哪些是违规求助? 3514739
关于积分的说明 11175783
捐赠科研通 3250115
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804951